European Commission Grants Orphan Medicinal Product Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




European Commission Grants Orphan Medicinal Product Designation to Nexavar for the Treatment of Hepatocellular Carcinoma

WEST HAVEN, C.T. and EMERYVILLE, C.A. -- April 18, 2006 -- Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc. announced today that Nexavar® (sorafenib) tablets has been granted orphan medicinal product status for the treatment of hepatocellular carcinoma (HCC), or liver cancer, by the European Commission.

This designation is based on a recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA).

"This orphan medicinal product designation demonstrates the European Commission's commitment to the study and development of treatments for rare diseases," said Susan Kelley, M.D., vice president, Oncology, Bayer Pharmaceuticals Corporation. "This support adds momentum to our research efforts with Nexavar and brings hope of a new treatment option to liver cancer patients in Europe."

SOURCE: Bayer Pharmaceuticals Corporation

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities